Two major medical groups just told millions of men the same clear thing: start with a PSA test, and do it on a schedule.
Story Snapshot
- Doctors should use PSA as the first test for prostate cancer screening, per new guidance.
- Average-risk men aged 50 to 69 should be offered screening every 2 to 4 years.
- Higher-risk men, including Black men and those with key gene changes or strong family history, should start earlier.
- Abnormal PSA does not mean rush to biopsy; MRI and biomarkers help avoid overtreatment.
What Changed And Why It Matters
The American Urological Association and the Society of Urologic Oncology issued a 2026 update that puts prostate-specific antigen, or PSA, at the front of the screening line. The exact instruction is plain: when screening, use PSA first. The groups wrapped that call inside a full pathway that covers when to test, when to pause, and how to follow up. The update aims to catch dangerous cancers while steering men away from needless biopsies and treatment for low-risk disease.
The update creates a steady plan for most men. Doctors should offer regular screening every 2 to 4 years to men ages 50 through 69. That window matches the age when prostate cancer risk begins to rise, but many men still have decades of life ahead. The schedule also gives room to adjust. Men can personalize screening or stop based on their values, age, PSA numbers, other risks, life expectancy, and overall health.
Who Should Start Earlier
The guidance puts a sharper focus on men who face higher risk. Doctors should offer screening from age 40 to 45 to people at increased risk because of Black race, harmful inherited gene changes such as BRCA2, or a strong family history with a father or brother who had prostate cancer. This is not a niche point. Black men face higher rates of prostate cancer and worse outcomes. Starting earlier aims to find threats sooner, when treatment can do the most good.
The American Cancer Society also stepped forward in 2026 to back routine PSA testing, with a simple clock: every two years for average-risk men aged 50 to 69, and yearly testing from ages 45 to 69 for Black men and some with strong family history. Two independent groups landing on regular PSA screening, with extra care for higher-risk men, gives families and clinicians a common playbook to use.
What Happens After An Elevated PSA
A single elevated PSA is not a diagnosis. PSA rises for reasons besides cancer, like infection or an enlarged prostate. The updated pathway reduces knee-jerk biopsies. If the PSA stays high on repeat testing, doctors should turn to magnetic resonance imaging and blood or urine biomarkers to sort risk before any biopsy decision. This step can cut false alarms and spare men from unneeded invasive procedures, while still flagging cancers that are likely to matter.
When a biopsy is needed, the guideline supports risk tools and shared decisions about treatment versus active surveillance. Many low-risk cancers can be watched safely. That choice can prevent treatment side effects like incontinence or erectile dysfunction. The aim is balance: find the aggressive tumors early and leave harmless ones alone whenever safe.
Where Groups Still Differ
Not every group lands on the same interval or age cutoffs. The American Urological Association and Society of Urologic Oncology recommend every 2 to 4 years for ages 50 to 69, while the American Cancer Society says every two years for average-risk men and annual testing for higher-risk men in midlife. The United States Preventive Services Task Force, a federal panel, advises men ages 55 to 69 to make an individual decision after talking with a clinician. The panel recommends against screening at age 70 and older. These differences reflect how groups weigh benefits and harms.
Our own Dr. Chris Anderson @CBAnderson2014 discusses the new @AmericanCancer Society prostate cancer screening guidelines on @CBSNews.https://t.co/g9hUhuo84i pic.twitter.com/xQdpxFUhru
— Columbia Urology (@ColumbiaUrology) November 13, 2026
Saving lives matters. So does avoiding waste, fear, and harm from overtreatment. The new urology guidance and the cancer society update both move toward that middle. They endorse PSA as the entry test, tighten the age lanes, and install brakes after an abnormal result. That respects patient choice, keeps the government from one-size-fits-all rules, and uses tools like magnetic resonance imaging to target care where it counts most.
How To Act On This Now
Men ages 50 to 69 at average risk should ask their doctor about PSA screening and set a two to four year plan. Black men, men with a father or brother who had prostate cancer, or men with a known BRCA2 mutation should ask about starting as early as 40 to 45. If a PSA comes back high, do not rush. Confirm with a repeat test. Discuss magnetic resonance imaging and biomarker testing before choosing biopsy. Review options carefully if cancer is found, including active surveillance for low-risk disease.
Sources:
auanet.org, cancer.gov, uspreventiveservicestaskforce.org, prostate.org.au
